Tradename: LANTIDRA

Proper Name: donislecel-jujn

Indication: Indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education.                     

Approval Date: 06/28/2023

Manufacturer: CellTrans Inc.


Leave a Reply

Your email address will not be published. Required fields are marked *